Arcus Biosciences (RCUS) Shares Outstanding (Weighted Average) (2016 - 2026)

Arcus Biosciences' Shares Outstanding (Weighted Average) history runs 11 years deep, the most recent figure standing at $125.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 27.44% year-over-year to $125.4 million; the TTM figure through Mar 2026 stood at $125.4 million (up 27.44% YoY), while the FY2025 annual figure was $107.4 million, up 19.2% from the prior year.
• Shares Outstanding (Weighted Average) was $125.4 million for Q1 2026 at Arcus Biosciences, up from $107.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $125.4 million in Q1 2026 to a low of $71.2 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $86.9 million across 5 years, with a median of $86.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) advanced 1.33% in 2022, then grew 27.44% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $72.0 million in 2022, then rose by 2.78% to $74.0 million in 2023, then grew by 21.76% to $90.1 million in 2024, then rose by 19.2% to $107.4 million in 2025, then climbed by 16.76% to $125.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $125.4 million (Q1 2026), $107.4 million (Q4 2025), and $103.7 million (Q3 2025), per Business Quant data.